| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1517/14656566.9.6.927 |
| P698 | PubMed publication ID | 18377336 |
| P2093 | author name string | James S Lewis | |
| John R Graybill | |||
| P2860 | cites work | Voriconazole therapeutic drug monitoring. | Q24542411 |
| Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis | Q28217179 | ||
| Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial | Q28277029 | ||
| Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial) | Q28298468 | ||
| International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobia | Q30453797 | ||
| Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase | Q33754208 | ||
| Interactions between triazoles and amphotericin B against Cryptococcus neoformans | Q33980497 | ||
| Germinated and nongerminated conidial suspensions for testing of susceptibilities of Aspergillus spp. to amphotericin B, itraconazole, posaconazole, ravuconazole, and voriconazole | Q33981488 | ||
| Correlation between antifungal susceptibilities of Coccidioides immitis in vitro and antifungal treatment with caspofungin in a mouse model | Q33982369 | ||
| Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate | Q33983618 | ||
| Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group | Q34002098 | ||
| Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis. | Q34143326 | ||
| Caspofungin | Q34199905 | ||
| Anidulafungin versus fluconazole for invasive candidiasis | Q34580316 | ||
| Efficacy of caspofungin against Aspergillus flavus, Aspergillus terreus, and Aspergillus nidulans | Q35215384 | ||
| Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization. | Q35745822 | ||
| Toward more effective antifungal therapy: the prospects of combination therapy. | Q35828187 | ||
| Micafungin: a new echinocandin | Q36436847 | ||
| Amphotericin B and fluconazole, a potent combination therapy for cryptococcal meningitis | Q36489747 | ||
| Studies of in vitro activities of voriconazole and itraconazole against Aspergillus hyphae using viability staining | Q38554220 | ||
| Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial | Q38922578 | ||
| Itraconazole-amphotericin B antagonism in Aspergillus fumigatus: an E-test-based strategy | Q39475550 | ||
| The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro | Q39652699 | ||
| Efficacy of caspofungin and voriconazole combinations in experimental aspergillosis. | Q42286250 | ||
| Why prior fluconazole use is associated with an increased risk of invasive mold infections in immunosuppressed hosts: an alternative hypothesis | Q43952852 | ||
| Comparison of caspofungin and amphotericin B for invasive candidiasis | Q44255071 | ||
| A comparative study of fungicidal activities of voriconazole and amphotericin B against hyphae of Aspergillus fumigatus | Q44357265 | ||
| Effect of increasing inoculum sizes of Aspergillus hyphae on MICs and MFCs of antifungal agents by broth microdilution method | Q44361670 | ||
| A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. | Q44440960 | ||
| Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin | Q44469440 | ||
| Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group | Q44474075 | ||
| Amphotericin B: time for a new "gold standard". | Q44527998 | ||
| A comparative study of the post-antifungal effect (PAFE) of amphotericin B, triazoles and echinocandins on Aspergillus fumigatus and Candida albicans | Q44733004 | ||
| Potential fungicidal effect of voriconazole against Candida spp. | Q45287249 | ||
| Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome | Q46758158 | ||
| Caspofungin: antifungal activity in vitro, pharmacokinetics, and effects on fungal load and animal survival in neutropenic rats with invasive pulmonary aspergillosis | Q46933151 | ||
| Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial | Q56970523 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 927-935 | |
| P577 | publication date | 2008-04-01 | |
| P1433 | published in | Expert Opinion on Pharmacotherapy | Q5421212 |
| P1476 | title | Fungicidal versus Fungistatic: what's in a word? | |
| P478 | volume | 9 |
| Q35962487 | A high-throughput screening assay for assessing the viability of Cryptococcus neoformans under nutrient starvation conditions. |
| Q33595937 | A high-throughput screening assay for fungicidal compounds against Cryptococcus neoformans |
| Q55455215 | Amplitude-modulated cold atmospheric pressure plasma jet for treatment of oral candidiasis: In vivo study. |
| Q34633649 | An investigation into the inhibitory effect of ultraviolet radiation on Trichophyton rubrum. |
| Q36434403 | Anidulafungin for the treatment of candidaemia/invasive candidiasis in selected critically ill patients. |
| Q35098733 | Anti-Candida activity of Quercus infectoria gall extracts against Candida species |
| Q92515646 | Antifungal activity of two oxadiazole compounds for the paracoccidioidomycosis treatment |
| Q37705308 | Antifungal adjuvants: Preserving and extending the antifungal arsenal |
| Q34048162 | Cryptococcus neoformans Site-2 protease is required for virulence and survival in the presence of azole drugs |
| Q59517219 | Effect of the Novel Antifungal Drug F901318 (Olorofim) on Growth and Viability of Aspergillus fumigatus |
| Q49679755 | MIC Distributions and Evaluation of Fungicidal Activity for Amphotericin B, Itraconazole, Voriconazole, Posaconazole and Caspofungin and 20 Species of Pathogenic Filamentous Fungi Determined Using the CLSI Broth Microdilution Method. |
| Q35270758 | Pharmacodynamics of echinocandins against Candida glabrata: requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hosts |
| Q26770692 | Potential Use of Phenolic Acids as Anti-Candida Agents: A Review |
| Q21559579 | Rapid identification of antifungal compounds against Exserohilum rostratum using high throughput drug repurposing screens |
| Q42319613 | SCY-078 Is Fungicidal against Candida Species in Time-Kill Studies |
| Q35191523 | Sertaconazole nitrate shows fungicidal and fungistatic activities against Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum, causative agents of tinea pedis |
| Q33725227 | Sterol regulatory element binding proteins in fungi: hypoxic transcription factors linked to pathogenesis |
| Q38066615 | The impact of azole resistance on aspergillosis guidelines |
| Q46504408 | Voriconazole treatment of invasive aspergillosis: real-world versus health-economic model results |
Search more.